IBMSC Resilient Industry and Supply Chain Enterprise (RISE) OTA Consortium

The Department of Health and Human Services' Administration for Strategic Preparedness and Response, through its Center for Industrial Base Management and Supply Chain (IBMSC), is seeking information from pharmaceutical and biomanufacturing industry partners to develop a potential consortium program focused on pandemic preparedness. The IBMSC Resilient Industry and Supply Chain Enterprise (RISE) OTA Consortium would expand and sustain domestic public health industrial base capabilities for manufacturing critical medical resources including drug substances, personal protective equipment, diagnostics, raw materials, and single-use consumables. Companies interested in either leading or participating in the consortium must demonstrate experience in manufacturing fill-finish drug services, PPE components, diagnostic materials, and digital manufacturing response networks. Respondents are required to submit a 10-page company description detailing their experience and infrastructure, plus unlimited additional pages addressing perspectives on participation barriers, government priority access during emergencies, capability sustainment during low-demand periods, and data sharing approaches. The RFI response deadline is July 13, 2025, at 8:00 AM EST, with submissions directed to Ashia.Everett@hhs.gov and Annette.Wright@hhs.gov.

This opportunity does not utilize any set-aside designations and is open to all qualified firms nationwide with no geographical performance limitations. No current contractors or incumbents are identified in the documentation, as this represents an early market research phase for a potential future consortium partnership program. The RFI does not specify award values or budget ranges, focusing instead on gathering industry feedback to inform the development of the consortium structure and requirements. Companies may express interest in serving as either the Consortium Lead or as participating members, with the government seeking to establish infrastructure and manufacturing capabilities that can be accessed during public health emergencies. The initiative aligns with multiple executive orders aimed at strengthening domestic manufacturing capacity and supply chain resilience in the medical and pharmaceutical sectors.